Literature DB >> 19650357

Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment.

Rochelle A Yanofsky1, Sashi S Seshia, Angelika J Dawson, Kent Stobart, Cheryl R Greenberg, Frances A Booth, Chitra Prasad, Marc R Del Bigio, Jens J Wrogemann, Francesca Fike, Richard A Gatti.   

Abstract

BACKGROUND: The onset of progressive cerebellar ataxia in early childhood is considered a key feature of ataxia-telangiectasia (A-T), accompanied by ocular apraxia, telangiectasias, immunodeficiency, cancer susceptibility and hypersensitivity to ionizing radiation.
METHODS: We describe the clinical features and course of three Mennonite children who were diagnosed with A-T following the completion of therapy for lymphoid malignancies.
RESULTS: Prior to cancer therapy, all had non-progressive atypical neurological abnormalities, with onset by age 30 months, including dysarthria, dyskinesia, hypotonia and/or dystonia, without telangiectasias. Cerebellar ataxia was noted in only one of the children and was mild until his death at age eight years. None had severe infections. All three children were "cured" of their lymphoid malignancies, but experienced severe adverse effects from the treatments administered. The two children who received cranial irradiation developed supratentorial primitive neuroectodermal tumors of the brain, an association not previously described, with fatal outcomes.
CONCLUSIONS: The range of neurological presentations of A-T is broad. Ataxia and telangiectasias may be minimal or absent and the course seemingly non-progressive. The diagnosis of A-T should be considered in all children with neuromotor dysfunction or peripheral neuropathy, particularly those who develop lymphoid malignancies. The consequences of missing the diagnosis may be dire. Radiation therapy and radiomimetic drugs should be avoided in individuals with A-T.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650357     DOI: 10.1017/s0317167100007794

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

1.  Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites.

Authors:  R Saunders-Pullman; D Raymond; A J Stoessl; D Hobson; K Nakamura; T Nakamura; S Pullman; D Lefton; M S Okun; R Uitti; R Sachdev; K Stanley; M San Luciano; J Hagenah; R Gatti; L J Ozelius; S B Bressman
Journal:  Neurology       Date:  2012-02-15       Impact factor: 9.910

2.  Clinical variability in ataxia-telangiectasia.

Authors:  Ebba Lohmann; Stefanie Krüger; Ann-Kathrin Hauser; Hasmet Hanagasi; Gamze Guven; Nihan Erginel-Unaltuna; Saskia Biskup; Thomas Gasser
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

3.  Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia-Telangiectasia.

Authors:  Roya Sherkat; Noushin Afshar Moghaddam; Nahid Reisi; Marzieh Rezaei
Journal:  Adv Biomed Res       Date:  2022-04-29

Review 4.  More Than Ataxia: Hyperkinetic Movement Disorders in Childhood Autosomal Recessive Ataxia Syndromes.

Authors:  Toni S Pearson
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-07-16

Review 5.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

6.  A new ataxia-telangiectasia mutation in an 11-year-old female.

Authors:  Esmaeil Mortaz; Sayed Mehran Marashian; Hosseinali Ghaffaripour; Mohammad Varahram; Payam Mehrian; Atosa Dorudinia; Johan Garssen; Ian M Adcock; Malcolm Taylor; Seyed Alireza Mahdaviani
Journal:  Immunogenetics       Date:  2017-05-09       Impact factor: 2.846

7.  Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia.

Authors:  Nils W Engel; Simon Schliffke; Ulrich Schüller; Christian Frenzel; Carsten Bokemeyer; Christian Kubisch; Davor Lessel
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

8.  Ataxia telangiectasia: A report of two cousins and review of literature.

Authors:  Anjali Sharma; Gurdeep Buxi; Rajbala Yadav; Ashok Kohli
Journal:  Indian J Med Paediatr Oncol       Date:  2011-10

9.  A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity.

Authors:  Kotoka Nakamura; Francesca Fike; Sara Haghayegh; Rachel Saunders-Pullman; Angelika J Dawson; Thilo Dörk; Richard A Gatti
Journal:  Mol Genet Genomic Med       Date:  2014-03-13       Impact factor: 2.183

10.  Dystonia in Ataxia Telangiectasia: A Case Report with Novel Mutations.

Authors:  Majid Zaki-Dizaji; Mohammad Tajdini; Fatemeh Kiaee; Hossein Shojaaldini; Reza Shervin Badv; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Oman Med J       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.